Charles River Laboratories International Inc
Change company Symbol lookup
Select an option...
CRL Charles River Laboratories International Inc
KIO KKR Income Opportunities Fund
BOAS BOA Acquisition Corp
ESBA Empire State Realty OP LP
ASGN ASGN Inc
CMS CMS Energy Corp
POWRU Powered Brands
VLDRW Velodyne Lidar Equity Warrants Exp 29 Sep 2025 *W EXP 09/29/2025
JPM JPMorgan Chase & Co
UVV Universal Corp
Go

Health Care : Life Sciences Tools & Services | Mid Cap Growth
Company profile

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company provides products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions in research and drug development. The Company operates through two segments: Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.

Premarket

Last Trade
Delayed
$312.32
0.08 (0.03%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$312.24
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
13

10-day average volume:
435,707
13

Company Profile

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company provides products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions in research and drug development. The Company operates through two segments: Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.

Valuation Ratios

Price/Earnings (TTM)
40.25x
Price/Sales (TTM)
4.58x
Price/Book (MRQ)
6.46x
Price/Cash Flow (TTM)
23.69x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

January 2022
Current Month
628.7K
Previous Month
690.9K
Percent of Float
1.26%
Days to Cover
1.1138 Days

Share Information

CRL is in a share class of common stock
Float
49.7M
Shares Outstanding
50.5M
Institutions Holding Shares
894
92.97%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • James C. FosterChmn.
  • David Ross SmithCFO
  • Birgit GirshickCOO
  • William D. BarboExec.VP
  • Joseph W. LaPlumeExec.VP

Address

Insider Trading

During the most recent quarter, 43K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.